Malignant pleural mesothelioma (MPM) is a highly lethal malignancy strongly associated with asbestos exposure (Peto et al, 1999). Owing to the long latency period of 20–40 years, the incidence of MPM is expected to increase dramatically over the next few decades despite the implementation of a ban on asbestos use in most countries since the 1980s. Estimations predict 250 000 people to die from MPM in Europe in the next 30 years and 2500–3000 new cases to be diagnosed each year in the United States (Peto et al, 1999; Robinson and Lake, 2005). The expected median survival of patients suffering from MPM is still poor, ranging from 4 to 12 months after diagnosis (Zucali and Giaccone, 2006). Aggressive cytoreductive therapy, including surgery (extrapleural pneumonectomy) in combination with chemotherapy and radiation (trimodality therapy), has been shown to prolong survival in selected patients with early MPM (Sugabaker et al, 1996). However, even the most successful current chemotherapy regimen (pemetrexed/cisplatin) prolongs median survival only by a few months (Vogelzang et al, 2003). Therefore, a better understanding of the mechanisms controlling malignant growth of MPM cells and the rational development of new therapeutic concepts with higher efficiency and defined cellular targets remains an important priority (Jackman, 2009).

Activins are members of the transforming growth factor β-(TGF-β) superfamily of growth and differentiation factors. Activin A, a homodimer of two βA subunits, has important physiological roles in cell differentiation, wound healing and inflammation (Werner and Alzheimer, 2006) and has the ability to either inhibit or promote growth, depending on the cell type. With respect to cancer, activin A was shown to inhibit cell proliferation in hepatocellular carcinoma (Chen et al, 2000), breast cancer (Burdette et al, 2005) or prostate cancer (Wang et al, 1996). Accordingly, tumours from these organs often show overexpression of activin antagonising proteins such as follistatin (Grusch et al, 2006) or FLRG (Razanajaona et al, 2007). In contrast, promotion of cell proliferation by activin A was demonstrated in endometrial carcinoma (Tanaka et al, 2004), oral squamous cell carcinoma (Chang et al, 2010) and several thoracic tumours, such as oesophageal squamous cell carcinoma (Yoshinaga et al, 2008), oesophageal adenocarcinoma (Seder et al, 2009a) and lung adenocarcinoma (Seder et al, 2009b). In these cancer types,
overexpression of activin A was found and often associated with poor prognosis, enhanced metastasis or a shorter disease-free survival time (Yoshinaga et al, 2003; Seder et al, 2009b; Chang et al, 2010). Moreover, downregulation of activin A gene expression via RNA interference reduced cell proliferation and invasion of cancer cells from these malignancies (Seder et al, 2009a,b; Chang et al, 2010), thus demonstrating the importance of activin A signalling for various carcinomas and suggesting activin A as a potential candidate for therapeutic interference.

In the present study, we show that activin A is highly expressed in MPM cell lines and in a subset of MPM tissue specimens. Furthermore, we demonstrate that inhibition of activin receptors or silencing of activin A gene expression impairs growth and migration of MPM cells.

MATERIALS AND METHODS

Cell culture

SPC111, SPC212 and M38K cells were established from biphasic MPM and kindly provided by Professor R Stahel (SPC11 and SPC212, University of Zurich, Zurich, Switzerland) and Professor Vl Kinnula (M38K, University of Helsinki, Helsinki, Finland). All other mesothelioma cell lines were from epitheloid MPM. The I2 MPM cell line was kindly provided by Professor A Catania (University of Milano, Milano, Italy). The CRL5820 and the non-transformed mesothelial cell line Met5a were purchased from the American Type Culture Collection (Manassas, VA, USA). P31 and their cisplatin-resistant derivative P31resl2 (established by in vitro cisplatin selection) were kindly provided by Professor K Gran kvist (University of Umea, Umea, Sweden). The VM6C and VM6C20 cell lines were established by our group following published protocols (Sagmeister et al, 2008). The MPM cell lines were maintained in RPMI1640 or MEM with 10% fetal calf serum regularly checked for Mycoplasma contamination.

RNA isolation, cDNA synthesis and real-time PCR

Isolation of total RNA from logarithmically growing cells was performed with TRIzol (Life Technologies, Carlsbad, CA, USA) and 2 µg RNA per sample were reverse transcribed with MMLV reverse transcriptase (Thermo Scientific, Waltham, MA, USA). One microtitre cDNA, corresponding to 50 ng RNA, was analysed per PCR. Quantitative real-time PCR (QPCR) was performed with Taqman assays or SYBR Green (Life Technologies), as previously described (Grusch et al, 2006), on an ABI Prism 7500 thermocycler (Life Technologies). Assay IDs, primer sequences and annealing temperatures are listed in Supplementary Tables S1 and S2. The ΔCt method using Met5a as calibrator. All expression analyses were performed in duplicates and repeated at least twice.

Tissue samples

Formalin-fixed, paraffin-embedded tumour tissue was available from 53 MPM patients resected between 1993 and 2010 at the Medical University of Vienna, Department of Surgery. All procedures were approved by the local Ethics Committee. Tissues were embedded during routine diagnostic work-up and coded by the Department of Pathology. Sections from each tumour block were cut at 4 µm. Haematoxylin and eosi staining was used to confirm the presence of invasive cancer.

Immunohistochemistry

Briefly, tissue sections were deparaffinised and rehydrated. After epitope retrieval, sections were incubated overnight at 4 °C with primary antibodies (anti activin A, AbD Serotec, Kidlington, UK; Ki67, Dako, Glostrup, Denmark; dilutions 1 : 100). Specificity of the activin A antibody was confirmed by immunoblotting using recombinant human (rh) activin A. Bound antibody on tissue sections was detected with the UltraVision LP detection system (Thermo Scientific). Colour development was done by 3,3′-diaminobenzidine and counterstaining by haematoxylin. Staining was evaluated by a thoracic pathologist unaware of the patients’ clinicopathological status. Only cytoplasmic staining of activin A was considered positive. Mean staining intensity was scored as absent (0), weak (1), moderate (2) or strong (3). The results were correlated with clinical/histological data using SPSS 17 software (SPSS Inc., Chicago, IL, USA).

Western blot analysis

Cells were seeded into six-well plates at a density of 3 × 10^5 per well. After 24 h, cells were incubated with rh activin A (20 ng ml^-1, R&D Systems, Minneapolis, MN, USA) for 30 min or transfected with siRNA oligonucleotides for 24 h as described below. Then proteins were extracted and processed for SDS-PAGE and immunoblotting as published (Hoda et al, 2011). The following primary antibodies were used: rabbit polyclonal to pSMAD2 (#3101), total SMAD2/3 (#3102), pERK1/2 (#9101), total ERK1/2 (#9102), mouse monoclonal to cyclin D1 (#2926), D2 (#2924) and D3 (#2936), rabbit monoclonal to β-tubulin (#2128) (all from Cell Signaling Technology, Danvers, MA, USA), mouse monoclonal to β-actin (Sigma, St Louis, MO, USA) at 1 : 1000 dilutions in PBS with 3% BSA. Horseradish peroxidase-coupled anti-rabbit/mouse antibodies (3% BSA, Dako) were used at 1 : 10 000 dilutions and blots developed with Western C reagent (Bio-Rad, Hercules, CA, USA). Bio-1D software (Vilber Lourmat, Eberhardzell, Germany) was used for band quantification.

Clonogenic assay

One thousand cells per well were seeded into six-well plates. After 24 h, one thousand cells were removed, cells were washed once with PBS and treated with 20 ng ml^-1 rh activin A (in PBS 0.1% BSA) or 2.5–20 nM of the activin receptor inhibitors SB-431542 or A-8301 (both from Tocris Bioscience, Bristol, UK) in DMSO. Controls were treated with solvent only. Treatment medium was renewed every 72 h. After 10–14 days, the medium was removed and colonies were stained with crystal violet. For photometric quantification, colonies were destained with 2% SDS and absorbance was measured at 562 nm using a SynergyHT plate reader and Gen5 software (BioTek, Winooski, VT, USA).

Scratch assay

Scratches were applied to confluent cultures in six-well plates using a pipette tip, medium was renewed and the indicated treatments were added. Scratches were photographed after 0, 4, 8, 24 and 48 h, and wound closure was calculated from the micrographs with Image J software (National Institutes of Health, Bethesda, MD, USA).

Cell viability assay

Cells were seeded in triplicates into 96-well plates at a density of 2 × 10^5 cells per well. The next day, medium was replaced with 100 µl fresh medium containing the indicated treatments and cells were incubated for 72 h. Cell viability was determined with the EZ4U kit (Biomedica, Vienna, Austria) following the manufacturer’s instructions. Absorbance was measured at 450 and 620 nm (as reference) as described above. Experiments were repeated at least three times.
Gene silencing

Cells were seeded into six-well plates at a density of $2 \times 10^5$ per well in full growth medium. The next day, cells were transfected with 50 nM siRNA targeting activin $\beta$A or non-silencing siRNA (both from Dharmacon, Lafayette, CO, USA) and Oligofectamine (Life Technologies) as transfection reagent. Cells were collected 48 h after transfection for determination of silencing efficiency by Taqman assays. Cell viability, colony formation and protein expression were tested as described above, except that clonogenic assays were performed in 12-well instead of 6-well plates.

Statistical analysis

Data are expressed as means ± s.d. from at least three individual experiments, except for staining scores, which are shown as box blots. Statistical significance of differences was determined by

---

**Figure 1** Expression of activin family genes in MPM cell models. RNA was extracted and reverse transcribed from subconfluent cultures of MPM cells and the non-malignant mesothelial cell line Met5a. The expression levels were determined with Taqman assays (activin subunits, A–D) or SYBR green real-time PCR (activin receptors, E–H) by the $2^{–\Delta\Delta CT}$ method using GAPDH for normalisation and Met5a as calibrator. Log 2 ratios of fold change compared with Met5a from at least two independent experiments performed in duplicates are shown.
using unpaired t-test, χ²-test or one-way or two-way ANOVA, as appropriate. P-values < 0.05 were considered statistically significant. Survival analysis was performed using Kaplan–Meier curves, log-rank test and the Cox-regression model.

RESULTS

Malignant pleural mesothelioma cell lines (over)express activin family members

The transcript levels of the activin subunits (βA, βB, βC and βE, Figure 1A–D) as well as the activin type I and type II receptors (ALK4, ALK7, ACVR2, ACVR2B, Figure 1E–H) were analysed using qPCR. Analyses were performed in nine MPM cell lines in comparison with the non-malignant mesothelial cell line Met5a. All cell lines expressed detectable levels of activin subunits as well as activin receptors. Importantly, the activin βA subunit, which has been previously linked to tumour aggressiveness in thoracic malignancies (Yoshinaga et al, 2008; Seder et al, 2009b), was elevated more than four-fold (log 2 ratio > 2) in six of nine MPM cell lines. Among the activin receptors, the type I receptors were mostly downregulated, whereas the type II receptor ACVR2 was upregulated. Activin signals are kept in balance by several antagonists such as follistatin, fstl3/FLRG, inhibin-α and TDGF1/cripto-1. However, none of these showed a clear trend of up- or downregulation in MPM cell lines (Supplementary Figure S1). No significant correlation was found between the expression level of the βA subunit and activin receptors or activin antagonists.

Activin A is highly expressed in epitheloid MPM tissue

As activin βA was overexpressed in the majority of MPM cell lines, we next tested, whether activin A is also present in tissue specimens from MPM patients. Paraffin-embedded tissue samples were available from 36 patients with epitheloid, 13 with biphasic and 4 with sarcomatoid MPM. Activin A staining of tumour cells is displayed as mean staining score for the three different histological subtypes (Figure 2A). Overall, 6 (11.3%), 20 (37.7%), 20 (37.7%) and 7 (13.2%) of the tumours had strong, moderate, weak or absent staining, respectively. Representative cases are shown in Figure 2B. There was a significant association of activin A expression with epitheloid vs non-epitheloid histology (P = 0.005), but not with patient survival, stage or nuclear Ki67 expression. In tumours with biphasic histology, activin A was predominantly present in the epithelial compartment.

Activin A stimulates growth and migration of MPM cells

Activin A has been connected to either apoptosis induction or more aggressive growth of tumour cells depending on the cell type.
Therefore, we next evaluated the response of MPM cells to activin A. First, we tested induction of SMAD signalling by activin A. When MPM cell lines were treated with recombinant activin A, an increase of phosphorylated SMAD2 was seen in all tested cell lines (Figure 3A). VMC20 and M38K also showed a considerable degree of SMAD2 activation in the absence of activin A treatment. No activation of MAP-kinase signalling (p38, ERK1/2) by activin A was seen in any of the cell lines (data not shown). When clonogenic growth/survival assays were performed, activin A induced a stimulation of up to 50% compared with mock-treated controls (Figure 3B and C). Also cell migration, analysed by scratch assay, was enhanced (Figure 3D). This demonstrates that activin A signal transduction via the canonical SMAD pathway is active in MPM cells and that MPM cells respond to activin A with increased growth and migration.

Inhibition of activin receptors impairs growth, clonogenicity and migration of MPM cells

As activin A supported MPM cell growth and MPM cell lines expressed activin βA, we next tested the dependency of MPM cell lines on activin receptor signals. Two different kinase inhibitors (SB-431542 and A-8301) targeting type I activin receptors (activin-like receptor kinases, ALK) were used. SB-431542 induced a dose-dependent inhibition of clonogenicity (Figure 4A). A similar growth inhibitory effect was also seen with A-8301, or when SMAD2 activation in the absence of activin A treatment. No activation of MAP-kinase signalling (p38, ERK1/2) by activin A was seen in any of the cell lines (data not shown). When clonogenic growth/survival assays were performed, activin A induced a stimulation of up to 50% compared with mock-treated controls (Figure 3B and C). Also cell migration, analysed by scratch assay, was enhanced (Figure 3D). This demonstrates that activin A signal transduction via the canonical SMAD pathway is active in MPM cells and that MPM cells respond to activin A with increased growth and migration.

Silencing of activin βA reduces viability and clonogenicity of MPM cells

As an additional proof for dependency of MPM cells on activin A, we silenced activin βA expression by siRNA. As shown in Figure 5A, a knockdown efficiency of around 75% was achieved when compared with respective mock controls (non-silencing siRNA). Again, a decrease of viability of 30–50% was seen in all cell models tested, except for P31, which showed no response in the short-term assay (Figure 5B). However, both P31 and its cisplatin-resistant derivative were inhibited in the clonogenic assay (Figure 5C).

To gain deeper insight into potential mechanisms underlying these effects, we analysed cyclin D expression and ERK1/2 phosphorylation of MPM cells in response to activin A silencing (Figure 6). Although cyclin D2 was not expressed at detectable levels, repression of cyclin D1 and cyclin D3 was observed in VMC20 cells and to a more moderate degree also in P31. Reduced ERK1/2 phosphorylation was only seen in the VMC20 cell line, whereas P31 showed a slight increase.

DISCUSSION

Despite considerable efforts to improve the outcome of patients suffering from MPM (Kelly et al, 2011), the prognosis remains still poor. This emphasises the urgent need for a better understanding of the molecular changes leading to the development of MPM, which could serve as basis for designing new molecularly targeted treatment strategies.

Activins represent possible interventional targets, as they are involved in the control of cell proliferation and differentiation, and are frequently deregulated in a variety of malignancies (Risbridger et al, 2001; Tsuchida et al, 2009). In liver cancer, for instance, tumour cells displayed decreased expression levels of activin A compared with normal hepatocytes (Vejda et al, 2003) and there is evidence for a decrease in activin signals in other cancer types such as breast and colorectal carcinoma (Jeruss et al, 2003; Jung et al, 2004). Interestingly, in tumour cells from these malignancies, treatment with activin A exerted growth-suppressive effects (Vejda et al, 2003; Burdette et al, 2005; Razanajaona et al, 2007) that we
recapitulated in the HepG2 hepatoma cells in this study (Supplementary Figure S2). In contrast, a pro-tumourigenic role of activin A via the tumour microenvironment has recently been demonstrated in a mouse model of skin tumourigenesis (Antsiferova et al, 2011). Similarly, increased activin A levels were found in thoracic malignancies, and treatment with activin A or ectopic overexpression of activin βA was associated with enhanced tumour cell aggressiveness (Yoshinaga et al, 2008; Seder et al, 2009a,b).

In MPM, previous studies demonstrated an inhibition of cell proliferation and tumour growth by antisense RNA to TGF-β (Fitzpatrick et al, 1994)—a cytokine of the same superfamily—but the role of activin signals in MPM has not been investigated so far. In the current study, we found increased expression of the activin subunits βA, βB and βC on the transcript level by QPCR in a panel of MPM cell lines, whereas in contrast to liver tumours (Grusch et al, 2006), melanoma (Stove et al, 2004) or breast cancer (Razanajaona et al, 2007), no consistent upregulation of the activin antagonists follistatin or FLRG was observed. Elevated expression of activin B or C has been reported in other malignancies as well (Gold et al, 2009; Frost et al, 2011), but their function in tumour biology remains largely uncharacterised. As activin A has previously been implicated in malignant progression, we focused the subsequent analysis on this member of the activin family.

Elevated activin A expression was confirmed by immunohistochemistry in tissue sections. This is in line with several recent publications, for instance in lung cancer (Seder et al, 2009b) oesophageal adenocarcinoma (Seder et al, 2009a) oral squamous cell carcinoma (Chang et al, 2010) and gastric cancer (Wang et al, 2010). Our results indicate that MPM is also characterised by increased rather than decreased activin A levels. However, in contrast to oral squamous cell carcinoma (Chang et al, 2010), stage I lung adenocarcinoma (Seder et al, 2009b) and gastric cancer in a Chinese population (Wang et al, 2010), expression was not associated with a worsened disease outcome. This could be explained by the rather heterogeneous patient collective as a result of different treatment approaches currently applied in MPM. Similar to phospho-mTOR (Hoda et al, 2011), activin A was

Figure 4  Activin receptor inhibition impairs MPM cell growth and migration. (A) The MPM cells (10^5 per well) were seeded into six-well plates and after 24 h treated with the indicated concentrations of SB-431542 or solvent (DMSO) as control for 10 days. Plates were stained with crystal violet and photographed. (B) Cells were seeded as in A and treated with 20 μM A-8301. Plates were destained with 2% SDS and absorption was measured at 562 nm. (C) A total of 2 x 10^5 cells per well were seeded into 96-well plates and treated the next day with 20 μM SB-431542 for 72 h. Cell viability was determined by MTT assay. (D) Cells were grown to near confluence in six-well plates and treated with SB-431542 or solvent after application of a scratch wound with a pipette tip. Wound closure was measured after 4, 8, 24 and 48 h. ***P<0.001.
associated with epitheloid histology, a histological subtype of MPM generally associated with a better outcome after trimodality treatment (Musk et al., 2011).

No previous reports have been published on the impact of activin A on MPM cell behaviour. Therefore, we tested on the one hand the effect of recombinant activin A, and on the other hand inhibition of activin receptors. Activin A stimulated clonogenic growth and enhanced cell migration similar to the findings described for activin A in oesophageal adenocarcinoma and lung adenocarcinoma (Seder et al., 2009a,b). Collectively, these data suggest that in each of these thoracic malignancies activin A has a tumour promoting rather than a tumour-suppressive effect. In colorectal and pancreatic carcinoma it was demonstrated that the growth inhibitory effect of activin A on tumour cells is lost by mutations in type I or type II activin receptors (Su et al., 2001; Hempen et al., 2003). In our MPM cell line series the main type I receptor for activin A (ALK4) was downregulated and the type II receptor ACVR2 was upregulated. However, the canonical activin/activin receptor/SMAD signalling axis was intact as evidenced by activin A-induced stimulation of SMAD2 phosphorylation.

Further confirming a pro-tumourigenic role of activin A in MPM, suppression of activin signals by two different inhibitors targeting activin receptor serine/threonine kinases led to a dose-dependent decrease of clonogenicity and, moreover, significantly delayed wound closure in scratch assays, reflecting an inhibitory effect on cell migration. As the available kinase inhibitors also target the TGF-β receptor ALK5 (Inman et al., 2002), we further confirmed our results more specifically by silencing activin expression with siRNA, which resulted in decreased viability both in short- and long-term assays.

Several reports have attributed effects of activin A to non-canonical activation of the MAPK pathway (Grusch et al., 2010) and to cell type-dependent positive (Ogawa et al., 2003) or negative (Yamato et al., 1997) regulation of cyclin D2 expression. Although stimulation with activin A for 30 min showed no indication for MAPK activation, VMC20 cells with high endogenous activin A expression and pSMAD2 levels responded to activin silencing with reduced levels of pERK, cyclin D1 and cyclin D3, which may at least in part explain the observed growth suppression. However, in contrast to a report on prostate cancer cells (Ying et al., 1997), no regulation of p53 by activin A treatment or silencing was observed in MPM cells (data not shown).

The finding that the kinase inhibitors had a greater antigrowth impact than the siRNA may implicate that also TGF-β has a role in MPM cell growth. This is in line with previous results (Suzuki et al., 2007) and has led to the initiation of a clinical study with a monoclonal antibody targeting TGF-β in relapsed MPM (http://ClinicalTrials.gov Identifier: NCT01112293). Our data indicate that also activin A may represent a potential target for intervention in MPM. In this regard, kinase inhibitors co-targeting TGF-β and activin receptors may even be of some advantage as increased efficiency of multitargeted approaches is also being discussed for tyrosine kinase inhibitors, for instance in lung cancer (Socinski, 2011).
ACKNOWLEDGEMENTS

We thank Barbara Dekan for perfect technical assistance with the Western blots. We acknowledge the Grant support by the Fund of the Western Blots. We knowledge the Grant support by the Fund of the

REFERENCES

Antisilerova M, Huber M, Meyer M, Piwko-Czuchra A, Ramadan T, Macleod AS, Havran WL, Dummer R, Hodi D, Werner S (2011) Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat Commun 2: 576

Burdeute JE, Jeruss JS, Kurlay SJ, Lee EJ, Woodruff TK (2005) Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 65: 7976–7979

Chang KP, Kao HK, Liang Y, Cheng MH, Chang TL, Liu SC, Lin YC, Ko TY, Lee PC, Lin CC, Tsai CL, Hsu PP, Hsu SP, Tsai CN (2010) Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression. Ann Surg Oncol 17: 1945–1954

Chen W, Woodruff TK, Mayo KE (2000) Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins. Endocrinology 141: 1263–1272

Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Gold E, Jetly N, O’Bryan MK, Meachem S, Srinivasan D, Behuria S, Sanchez-Mejia GO, Williamson AI, Kopp M (2006) Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol 45: 673–680

Frost K, Seir K, Lackner A, Grusl M, Grasl-Kraub P, Schulte-Hermann R, Rodgarkia-Dara C (2011) Inhibin/activin expression in human and rodent liver: subunits alpha and beta as new players in human hepatocellular carcinoma? Br J Cancer 104: 1303–1312

Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping CJ, Hruban RH, Kern SE (2003) Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in pancreatic carcinoma. J Thorac Oncol 4: 653–662

Kelly RJ, Sharon E, Hassan R (2011) Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 73: 256–263

Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, Sleight J, Hammond N, Threlfall T, Shlikin KB, de Klerk NH (2011) Predicting survival in malignant mesothelioma. Eur Respir J 38: 1420–1424

ogawa T, Yogo K, Ishida N, Takeya T (2003) Synergistic effects of activin and FSH on hyperphosphorylation of Rb and G1/S transition in rat primary granulosa cells. Mol Cell Endocrinol 210: 31–38

Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemiology. Br J Cancer 79: 666–672

Rodgarkia-Dara C (2011) Inhibin/activin expression in human and rodent liver: subunits alpha and beta as new players in human hepatocellular carcinoma? Br J Cancer 104: 1303–1312

Seder CW, Hartojo W, Bansal R, Murphy KM, Montgomery E, Yeo CJ, Hruban RH, Kern SE (2001) ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic adenocarcinoma cells. Oncol Rep 8: 2351–2359

Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, Ling LE (2007) A novel small-molecule inhibitor of transforming growth factor beta type I receptor inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351–2359

Tanaka T, Tougima S, Umesaki N (2004) Activin A inhibitor growth-inhibitory signals by TGF-beta1 in differentiated human endometrial cells. Mol Pharmacol 65: 1263–1272

Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H, Inokuchi K (2009) Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 7: 15

Veja S, Erlach N, Peter B, Drucker C, Rossmanith W, Pohli J, Schulte-Hermann R, Grusl M (2003) Expression of activins A and B induces apoptosis in human and rat hepatoma cells. Carcinogenesis 24: 1801–1809

City of Vienna for Innovative Interdisciplinary Cancer Research to MAH and by the Herzfelder Foundation to MG.

Conflict of interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636–2644

Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, Yan DW, Tang HM, Peng ZH (2010) Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol 29(1): 77–83

Wang QF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley Jr. WF, Sluss PM (1996) Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology 137: 5476–5483

Werner S, Alzheimer C (2006) Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev 17: 157–171

Yamato K, Koseki T, Ohguchi M, Kizaki M, Ikeda Y, Nishihara T (1997) Activin A induction of cell-cycle arrest involves modulation of cyclin D2 and p21CIP1/WAF1 in plasmacytotic cells. Mol Endocrinol 11: 1044–1052

Ying S, Zhang Z, Batres Y, Zhao Y, Lin S, Li G (1997) p53 is involved in the inhibition of cell proliferation mediated by activin A in cultured human prostate cancer LNCaP cells. Int J Oncol 11: 591–595

Yoshinaga K, Mimori K, Yamashita K, Utsunomiya T, Inoue H, Mori M (2003) Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol 22: 75–80

Yoshinaga K, Yamashita K, Mimori K, Tanaka F, Inoue H, Mori M (2008) Activin a causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells. Ann Surg Oncol 15: 96–103

Zucali PA, Giaccone G (2006) Biology and management of malignant pleural mesothelioma. Eur J Cancer 42: 2706–2714

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.